Overview

NeuroSkye Therapeutics is a translational biotechnology company developing human BBB and blood-tumor-barrier (BTB) functional diagnostic platforms to inform treatment decisions in brain tumors. Operating at the intersection of neuro-oncology, precision diagnostics, and translational medicine, NeuroSkye addresses a critical gap in therapy selection by evaluating drug delivery feasibility across the BBB/BTB, enabling more informed, delivery-based clinical decision support and recurrence planning.